Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2013 1
2014 3
2015 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Porter DL, et al. N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10. N Engl J Med. 2011. PMID: 21830940 Free PMC article. Clinical Trial.
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH. Guedan S, et al. Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1. Blood. 2014. PMID: 24986688 Free PMC article.
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH. Frigault MJ, et al. Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19. Cancer Immunol Res. 2015. PMID: 25600436 Free PMC article.
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. Kalos M, et al. Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842. Sci Transl Med. 2011. PMID: 21832238 Free PMC article. Clinical Trial.
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.
Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Barrett DM, et al. Cytotherapy. 2014 May;16(5):619-30. doi: 10.1016/j.jcyt.2013.10.013. Epub 2014 Jan 16. Cytotherapy. 2014. PMID: 24439255 Free PMC article.
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Singh N, et al. Cancer Immunol Res. 2014 Nov;2(11):1059-70. doi: 10.1158/2326-6066.CIR-14-0051. Epub 2014 Aug 7. Cancer Immunol Res. 2014. PMID: 25104548 Free PMC article.
Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA. Barrett DM, et al. Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23. Hum Gene Ther. 2011. PMID: 21838572 Free PMC article.
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH. Zhao Y, et al. Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20926399 Free PMC article.
Feedback